Insulet (NASDAQ:PODD) Hits New 12-Month Low - Should You Sell?

Key Points

• Insulet hit a new 52-week low, trading as low as $216.05 (last ~$216.12) on heavy volume and down about 4.2% from the prior close.
• Several firms have trimmed price targets (e.g., JPMorgan $415→$340, Oppenheimer $365→$300; TD Cowen cut to Hold at $294), but the consensus remains a Moderate Buy with an average target of $354.24.
• Operationally the company beat Q1 estimates (EPS $1.55 vs. $1.48, revenue $783.8M, +31.2% YoY), yet the stock trades below its 50- and 200-day moving averages and carries a high P/E (~61.7), reflecting valuation and sentiment pressure.

Insulet Corporation (NASDAQ:PODD - Get Free Report) shares hit a new 52-week low on Wednesday . The company traded as low as $216.05 and last traded at $216.1160, with a volume of 585871 shares trading hands. The stock had previously closed at $225.50.

Analysts Set New Price Targets

Several brokerages have recently commented on PODD. JPMorgan Chase & Co. decreased their price objective on shares of Insulet from $415.00 to $340.00 and set an "overweight" rating on the stock in a report on Thursday, February 19th. Leerink Partners dropped their target price on shares of Insulet from $386.00 to $360.00 and set an "outperform" rating for the company in a report on Thursday, February 19th. TD Cowen cut Insulet from a "buy" rating to a "hold" rating and set a $294.00 price target on the stock. in a research note on Monday, January 26th. BTIG Research restated a "buy" rating and set a $380.00 price target on shares of Insulet in a research report on Wednesday, February 18th. Finally, Oppenheimer dropped their price objective on Insulet from $365.00 to $300.00 and set an "outperform" rating for the company in a research note on Thursday, February 19th. Twenty investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $354.24.

Insulet Stock Down 4.2%

The business's fifty day moving average is $250.03 and its two-hundred day moving average is $291.12. The stock has a market cap of $15.21 billion, a price-to-earnings ratio of 61.71, a PEG ratio of 1.36 and a beta of 1.42. The company has a quick ratio of 2.15, a current ratio of 2.81 and a debt-to-equity ratio of 0.61.

Insulet (NASDAQ:PODD - Get Free Report) last released its earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.48 by $0.07. Insulet had a net margin of 9.12% and a return on equity of 24.90%. The company had revenue of $783.80 million for the quarter, compared to analyst estimates of $768.31 million. During the same period in the prior year, the business earned $1.15 EPS. The firm's quarterly revenue was up 31.2% on a year-over-year basis. Equities analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Michael R. Minogue acquired 2,030 shares of Insulet stock in a transaction dated Wednesday, February 25th. The shares were acquired at an average cost of $246.23 per share, for a total transaction of $499,846.90. Following the completion of the purchase, the director owned 17,483 shares in the company, valued at approximately $4,304,839.09. The trade was a 13.14% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.39% of the company's stock.

Institutional Investors Weigh In On Insulet

Large investors have recently bought and sold shares of the stock. Rockefeller Capital Management L.P. grew its position in shares of Insulet by 488.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 3,343 shares of the medical instruments supplier's stock worth $950,000 after buying an additional 2,775 shares in the last quarter. Corient Private Wealth LLC increased its stake in shares of Insulet by 35.0% during the fourth quarter. Corient Private Wealth LLC now owns 14,595 shares of the medical instruments supplier's stock worth $4,160,000 after buying an additional 3,782 shares during the period. Sit Investment Associates Inc. raised its holdings in Insulet by 13.9% in the fourth quarter. Sit Investment Associates Inc. now owns 18,634 shares of the medical instruments supplier's stock valued at $5,297,000 after acquiring an additional 2,277 shares in the last quarter. MidFirst Bank acquired a new stake in Insulet in the fourth quarter valued at approximately $394,000. Finally, Kera Capital Partners Inc. raised its holdings in Insulet by 92.0% in the fourth quarter. Kera Capital Partners Inc. now owns 1,966 shares of the medical instruments supplier's stock valued at $559,000 after acquiring an additional 942 shares in the last quarter.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.